184 related articles for article (PubMed ID: 22694778)
1. Effects of olmesartan on arterial stiffness in rats with chronic renal failure.
Chuang YC; Wu MS; Su YK; Fang KM
Cardiovasc Diabetol; 2012 Jun; 11():66. PubMed ID: 22694778
[TBL] [Abstract][Full Text] [Related]
2. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Paulis L; Becker ST; Lucht K; Schwengel K; Slavic S; Kaschina E; Thöne-Reineke C; Dahlöf B; Baulmann J; Unger T; Steckelings UM
Hypertension; 2012 Feb; 59(2):485-92. PubMed ID: 22215717
[TBL] [Abstract][Full Text] [Related]
3. Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness.
Nguy L; Johansson ME; Grimberg E; Lundgren J; Teerlink T; Carlström M; Lundberg JO; Nilsson H; Guron G
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(9):R744-52. PubMed ID: 23515616
[TBL] [Abstract][Full Text] [Related]
4. L-carnitine ameliorates oxidative damage due to chronic renal failure in rats.
Sener G; Paskaloğlu K; Satiroglu H; Alican I; Kaçmaz A; Sakarcan A
J Cardiovasc Pharmacol; 2004 May; 43(5):698-705. PubMed ID: 15071358
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways.
Abo El-Nasr NME; Saleh DO; Mahmoud SS; Nofal SM; Abdelsalam RM; Safar MM; El-Abhar HS
Eur J Pharmacol; 2020 May; 874():173010. PubMed ID: 32067934
[TBL] [Abstract][Full Text] [Related]
6. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome.
Raff U; Walker S; Ott C; Schneider MP; Schmieder RE
J Clin Hypertens (Greenwich); 2015 Feb; 17(2):98-104. PubMed ID: 25537177
[TBL] [Abstract][Full Text] [Related]
8. Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats.
Porteri E; Rodella L; Rizzoni D; Rezzani R; Paiardi S; Sleiman I; De Ciuceis C; Boari GE; Castellano M; Bianchi R; Agabiti-Rosei E
Blood Press; 2005; 14(3):184-92. PubMed ID: 16036499
[TBL] [Abstract][Full Text] [Related]
9. Melatonin ameliorates chronic renal failure-induced oxidative organ damage in rats.
Sener G; Paskaloglu K; Toklu H; Kapucu C; Ayanoglu-Dulger G; Kacmaz A; Sakarcan A
J Pineal Res; 2004 May; 36(4):232-41. PubMed ID: 15066047
[TBL] [Abstract][Full Text] [Related]
10. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.
Takahashi T; Konta T; Takasaki S; Ichikawa K; Takeishi Y; Kubota I
Clin Exp Nephrol; 2007 Sep; 11(3):202-208. PubMed ID: 17891346
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease.
Nishihara M; Takesue K; Hirooka Y
Clin Exp Hypertens; 2019; 41(3):211-219. PubMed ID: 29694249
[TBL] [Abstract][Full Text] [Related]
12. Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats.
Endo S; Mori T; Yoneki Y; Nakamichi T; Hosoya T; Ogawa S; Tokudome G; Hosoya T; Miyata T; Ito S
Hypertens Res; 2009 Jun; 32(6):513-9. PubMed ID: 19407824
[TBL] [Abstract][Full Text] [Related]
13. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.
Kadowaki D; Anraku M; Tasaki Y; Taguchi K; Shimoishi K; Seo H; Hirata S; Maruyama T; Otagiri M
Biol Pharm Bull; 2009 Dec; 32(12):2041-5. PubMed ID: 19952425
[TBL] [Abstract][Full Text] [Related]
14. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
Mizuno M; Sada T; Kato M; Fukushima Y; Terashima H; Koike H
J Cardiovasc Pharmacol; 2006 Oct; 48(4):135-42. PubMed ID: 17086090
[TBL] [Abstract][Full Text] [Related]
15. Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.
Satheesan S; Figarola JL; Dabbs T; Rahbar S; Ermel R
Br J Pharmacol; 2014 Jun; 171(12):3103-14. PubMed ID: 24611770
[TBL] [Abstract][Full Text] [Related]
16. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.
Kaiqiang Ji ; Minakawa M; Fukui K; Suzuki Y; Fukuda I
Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):103-11. PubMed ID: 19171689
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
Nishio M; Sakata Y; Mano T; Yoshida J; Ohtani T; Takeda Y; Miwa T; Masuyama T; Yamamoto K; Hori M
J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
[TBL] [Abstract][Full Text] [Related]
18. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats.
Gounder VK; Arumugam S; Arozal W; Thandavarayan RA; Pitchaimani V; Harima M; Suzuki K; Nomoto M; Watanabe K
Int Immunopharmacol; 2014 Feb; 18(2):282-9. PubMed ID: 24291173
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.
Jo F; Morimoto S; Nakahigashi M; Kusabe M; Someya K; Morita T; Jo H; Imada T; Kosaki A; Toyoda N; Nishikawa M; Iwasaka T
Kidney Blood Press Res; 2011; 34(6):418-23. PubMed ID: 21709422
[TBL] [Abstract][Full Text] [Related]
20. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
